Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory Phenotype

27 Sept 2019

Abstract excerpt

BACKGROUND: The inhibition of Janus kinases (JAKs) and subsequent signal transducers and activators of transcription (STATs) by tofacitinib represents a new therapeutic strategy in inflammatory bowel diseases (IBD) as clinical trials have led to approval of tofacitinib for ulcerative colitis (UC) and hint at a possible efficacy for Crohn`s disease (CD). However, the impact of tofacitinib on cellular response of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Inflammatory Bowel Disease
Share to Psoriasis: Treatment and Pathogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31560043
DOI: 10.1093/ibd/izz213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory PhenotypePMID 31560043Read ↗

JAK/STAT Inhibition Reprograms T Cell Activation and Metabolism in Inflammatory Arthritis PatientsSemantic proximity Read ↗

The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development.Semantic proximity Read ↗

Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s diseaseSemantic proximity Read ↗

A JAK-STAT-activated myeloid hub at ulceration sites underlies resistance to anti-TNF therapy in Crohn’s diseaseSemantic proximity Read ↗

Understanding the mechanisms underlying the lack of response to Janus kinase inhibition in ulcerative colitisSemantic proximity Read ↗

The Cell-Specific Effects of JAK1 Inhibitors in Ulcerative ColitisSemantic proximity Read ↗

Discordant effects of <i>ex-vivo</i> JAK inhibition on inflammatory responses in colonic compared to ileal mucosaSemantic proximity Read ↗

Evaluation of the effect of GM-CSF blocking on the phenotype and function of human monocytes.Semantic proximity Read ↗

Exhaustion profile on classical monocytes after LPS stimulation in patients with Crohn’s diseaseSemantic proximity Read ↗

JAK and TYK2 inhibitors differentially modulate interferon/TNF-driven inflammation, stemness and proliferation in the colonic epithelium of ulcerative colitisSemantic proximity Read ↗

Activated type 17 helper T cells affect tofacitinib treatment outcomesSemantic proximity Read ↗

Interferon-Beta Induces Distinct Gene Expression Response Patterns in Human Monocytes versus T cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.